Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design: HEPATOLOGY, Vol. 00, No. X, 2013 REIG ET AL.

Open access
Reig, Maria, Rimola, Jordi, Torres, Ferran, Darnell, Anna, Rodriguez-Lope, Carlos, Forner, Alejandro, LLarch, Neus, Ríos, José, Ayuso, Carmen, Bruix, Jordi·2013·Hepatology

Abstract

UNLABELLED: Sorafenib improves overall survival (OS) of patients with hepatocellular carcinoma (HCC) in the absence of objective response. Thus, time to tumor progression (TTP) is used to capture benefits of novel molecular agents, but proof of its surrogacy with survival is lacking. Furthermore, survival predictors upon progression are not established and there is a need to characterize postprogression survival (PPS) and assess with time-dependent covariates analysis if it is influenced by progression pattern, and not solely by simultaneous impairment of liver function and performance status. We prospectively followed HCC patients treated with sorafenib. Clinical and biochemical evaluation were done every 4 weeks. Radiologic assessment of progression was done at week 4 and then every 8 weeks using RECIST 1.1. The progression pattern was divided into: intrahepatic/extrahepatic increase in tumor size, new intrahepatic lesion, and new extrahepatic lesion (NEH). We included 147 patients (hepatitis C virus [HCV] 57.1%, performance status [PS] 0 83.6%, Child-Pugh A 82.3%, and BCLC-C 47.3%). The median OS was 12.7 months and its independent predictors (hazard ratio [HR], 95% confidence interval [CI]) were: baseline BCLC 2.49 [1.66-3.73], PS 1.86 [1.12-3.10], registration during follow-up of Child-Pugh B or Child-Pugh C scores (2.36 [1.51-3.69] and 2.89 [1.62-5.15], respectively), definitive sorafenib interruption 2.48 [1.54-4.01], and TTP 3.39 [1.89-6.1]. The presence of NEH 2.42 [1.32-4.44] is also an independent predictor of OS and PPS in patients with radiologic progression. CONCLUSION: Tumor progression is a surrogate of survival but its impact varies according to progression pattern. Thus, PPS is influenced by progression pattern and this is key in prognostic prediction and second-line trial design and analysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.26586

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 257

Metadata

Authors
Reig, M., Rimola, J., Torres, F., Darnell, A., Rodriguez-Lope, C., Forner, A., LLarch, N., Ríos, J., Ayuso, C., & Bruix, J.
Venue
Hepatology
Published
2013-10-29
Volume
58
Issue
6
Pages
2023-2031
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1739036892
Cited by
257
References
20
FWCI
11.74
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design: HEPATOLOGY, Vol. 00, No. X, 2013 REIG ET AL. https://app.cochat.ai/papers/10.1002/hep.26586
The paper
Reig, M., Rimola, J., Torres, F., Darnell, A., Rodriguez-Lope, C., Forner, A., LLarch, N., Ríos, J., Ayuso, C., & Bruix, J. (2013). Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design: HEPATOLOGY, Vol. 00, No. X, 2013 REIG ET AL. Hepatology. https://doi.org/10.1002/hep.26586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.